Discovery of 2-(cyclohexylmethylamino)pyrimidines as a new class of reversible valosine containing protein inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10443-10454

  Cervi, Giovanni ^a   Magnaghi, Paola ^a   Asa, Daniela ^a   Avanzi, Nilla ^a   Badari, Alessandra ^a   Borghi, Daniela ^a   Caruso, Michele ^a   Cirla, Alessandra ^a   Cozzi, Liviana ^a   Felder, Eduard ^a   Galvani, Arturo ^a   Gasparri, Fabio ^a   Lomolino, Antonio ^a   Magnuson, Steven ^b   Malgesini, Beatrice ^a   Motto, Ilaria ^a   Pasi, Maurizio ^a   Rizzi, Simona ^a   Salom, Barbara ^a   Sorrentino, Graziella ^a   Troiani, Sonia ^a   Valsasina, Barbara ^a   O'Brien, Thomas ^b   Isacchi, Antonella ^a   Donati, Daniele ^a   D'Alessio, Roberto ^a   more..

^a Medical Oncology   (Italy)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(6 CHLORO 2 METHYLSULFANYLPYRIMIDIN 4 YL)PHENYLAMINE; 4 (4 METHYL 6 PHENYLPYRIMIDIN 2 YLSULFANYLMETHYL)BENZOIC ACID; 4 (4 METHYL 6 PHENYLPYRIMIDINE 2 SULFONYLMETHYL)BENZOIC ACID; 4 [(4 (2 METHYLBENZYLAMINO) 6 PHENYLPYRIMIDIN 2 YLAMINO]METHYL]CYCLOHEXANECARBOXYLIC ACID AMIDE; 4 [(4 BENZYLAMINO 6 CHLOROPYRIMIDIN 2 YLAMINO)METHYL]CYCLOHEXANECARBOXYLIC ACID AMIDE; 4 [(4 BENZYLAMINO 6 CHLOROPYRIMIDIN 2 YLAMINO)METHYL]CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER; 4 [(4 BENZYLAMINO 6 PHENYLPYRIMIDIN 2 YLAMINO)METHYL] CYCLOHEXANECARBOXYLIC ACID; 4 [(4 BENZYLAMINO 6 PHENYLPYRIMIDIN 2 YLAMINO)METHYL] CYCLOHEXANECARBOXYLIC ACID AMIDE; 4 [(4 CHLORO 6 PHENYLAMINOPYRIMIDIN 2 YLAMINO)METHYL]CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER; 4 [(4 CHLORO 6 PHENYLPYRIMIDIN 2 YLAMINO)METHYL] CYCLOHEXANECARBOXYLIC ACID AMIDE; 4 [(4 CHLORO 6 PHENYLPYRIMIDIN 2 YLAMINO)METHYL] CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER; 4 [(4 PHENYL 6 PHENYLAMINOPYRIMIDIN 2 YLAMINO)METHYL]CYCLOHEXANECARBOXYLIC ACID; 4 [(4,6 DI PHENYLPYRIMIDIN 2 YLAMINO)METHYL] CYCLOHEXANECARBOXYLIC ACID; 4 [(6 OXO 4 PHENYL 1,6 DIHYDROPYRIMIDIN 2 YLAMINO)METHYL]CYCLOHEXANECARBOXYLIC ACID ETHYL ESTER; 4 [[4 BENZYLAMINO 6 (2 FLUOROPHENYL)PYRIMIDIN 2 YLAMINO]METHYL]CYCLOHEXANECARBOXYLIC ACID AMIDE; BENZYL (6 CHLORO 2 METHYLSULFANYLPYRIMIDIN 4 YL)AMINE; FUNGAL PROTEIN; PROTEIN INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALOSINE CONTAINING PROTEIN; ADENOSINE TRIPHOSPHATASE; CDC48 PROTEIN; CELL CYCLE PROTEIN; ENZYME INHIBITOR; PYRIMIDINE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROLYSIS; IMMUNOBLOTTING; MASS SPECTROMETRY; MICROWAVE COOKING; MICROWAVE IRRADIATION; MOLECULAR MODEL; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HCT116 CELL LINE; METABOLISM;

ADENOSINE TRIPHOSPHATASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; DRUG DISCOVERY; ENZYME INHIBITORS; HCT116 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920114740     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501313x     Document Type: Article

References (21)

1. Ogura, T.; Wilkinson, A. J. AAA+ superfamily ATPases: common structure-diverse function Genes Cells 2001, 6, 575-597
2. Wang, Q.; Changcheng Song, C.; Li, C. H. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions J. Struct. Biol. 2004, 146, 44-57
3. DeLaBarre, B.; Brunger, A. T. Nucleotide dependent motion and mechanism of action of p97/VCP J. Mol. Biol. 2005, 347, 437-452
4. Davies, J. M.; Brunger, A. T.; Weis, W. I. Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotide-dependent conformational change Structure 2008, 16, 715-726
5. Yamamoto, S.; Tomita, Y.; Nakamori, S.; Hoshida, Y.; Nagano, H.; Dono, K.; Umeshita, K.; Sakon, M.; Monden, M.; Aozasa, K. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence J. Clin. Oncol. 2003, 21 (3) 447-452
6. Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Takiguchi, S.; Fujiwara, Y.; Yasuda, T.; Yano, M.; Nakamori, S.; Sakon, M.; Monden, M.; Katsuyuki Aozasa, K. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma J. Clin. Oncol. 2003, 21 (13) 2537-2544
7. Kakizuka, A. Roles of VCP in human neurodegenerative disorders Biochem. Soc. Trans. 2008, 36 (Part 1) 105-108
8. Wang, Q.; Shinkre, B. A.; Lee, J.; Weniger, M. A.; Liu, Y.; Chen, W.; Wiestner, A.; Trenkle, W. C.; Ye, Y. The ERAD inhibitor eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group PLoS One 2010, 5 (11) e15479
9. Choua, T.; Brownb, S. J.; Minondc, D.; Nordind, B. E.; Lie, K.; Jonesf, A. C.; Chasec, P.; Porubskye, P. R.; Stoltzf, B. M.; Schoenene, F. J.; Patricellid, M. P.; Hodderc, P.; Rosenb, H.; Deshaies, R. J. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (12) 4834-4839
10. Bursavich, M. G.; Parkera, D. P.; Willardsena, J. A.; Gaob, Z.; Davisb, T.; Ostaninb, K.; Robinsonb, R.; Petersonb, A.; Cimborab, D. M.; Zhub, J.; Richards, B. 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97) Bioorg. Med. Chem. Lett. 2010, 20 (5) 1677-1679
11. Chou, T.; Li, K.; Frankowski, K. J.; Schoenen, F. J.; Deshaies, R. J. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase ChemMedChem 2013, 8, 297-312
12. Polucci, P.; Magnaghi, P.; Angiolini, M.; Asa, D.; Avanzi, N.; Badari, A.; Bertrand, J.; Casale, E.; Cauteruccio, S.; Cirla, A.; Cozzi, L.; Galvani, A.; Jackson, P. K.; Liu, Y.; Magnuson, S.; Malgesini, B.; Nuvoloni, S.; Orrenius, C.; Sirtori, F. R.; Riceputi, L.; Rizzi, S.; Trucchi, B.; O'Brien, T.; Isacchi, A.; Donati, D.; D'Alessio, R. Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships J. Med. Chem. 2013, 56, 437-450
13. Goswami, S.; Hazra, A.; Jana, S. One-pot two-step solvent-free rapid and clean synthesis of 2-(substituted amino)-pyrimidines by mirowave irradiation Bull. Chem. Soc. Jpn. 2009, 82, 1175-1181
14. Umeda, Y.; Moriguchi, M.; Kuroda, H.; Nakamura, T.; Iinuma, H.; Takeuchi, T.; Humezawa, H. Synthesis and antitumor activity of spergualin analogues J. Antibiot. 1985, 38 (No. 7) 886-898
15. Ceide, S. C.; Montalban, A. G. Microwave-assisted, efficient and regioselective Pd-catalyzed C-phenylation of halopyrimidines Tetrahedron Lett. 2006, 47 (26) 4415-4418
16. Magnaghi, P.; D'alessio, R.; Valsasina, B.; Avanzi, N.; Rizzi, S.; Asa, D.; Gasparri, F.; Cozzi, L.; Cucchi, U.; Orrenius, C.; Polucci, P.; Ballinari, D.; Perrera, C.; Leone, A.; Cervi, G.; Casale, E.; Xiao, Y.; Wong, C.; Anderson, D. J.; Galvani, A.; Donati, D.; O'Brien, T.; Jackson, P. K.; Isacchi, A. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death Nat. Chem. Biol. 2013, 9 (9) 548-556
17. Hopkins, A. L.; Keserü, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121
18. Fröhlich, K. U.; Fries, H. W.; Peters, J. M.; Mecke, D. The ATPase activity of purified CDC48p from Saccharomyces cereuisiae shows complex dependence on ATP-, ADP-, and NADH-concentrations and is completely inhibited by NEM Biochim. Biophys. Acta 1995, 1253, 25-32
19. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A.. Gaussian 03, revision C.02; Gaussian, Inc.: Wallingford, CT, 2004.
20. Schaftenaar, G.; Noordik, J. H. Molden: a pre- and post-processing program for molecular and electronic structures J. Comput.-Aided Mol. Des. 2000, 14, 123-134
21. McMartin, C.; Bohacek, R. S. QXP: powerful, rapid computer algorithms for structure-based drug design J. Comput.-Aided Mol. Des. 1997, 11, 333-344